Gore Range Capital
Gore Range Capital is a New York- and Southlake, Texas-based healthcare venture capital firm founded in 2015 that invests $5M–$15M in early-stage skin-health, regenerative medicine, and longevity companies, serving portfolio founders and limited partners through its Fund I and nine-figure Fund II.
- Company typePrivate
- Founded2015
- HeadquartersNew York, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Gore Range Capital does
Gore Range Capital is a specialized healthcare venture capital firm founded in 2015 by Ethan Rigel and Humberto Antunes, initially based in New York and relocated to Southlake, Texas (Dallas-Fort Worth) in 2020–2021 to align with the regional skin-health cluster anchored by Galderma. The firm invests in early-stage healthcare companies developing next-generation platforms across precision health, regenerative medicine, personalized therapeutics, longevity, and aesthetic dermatology, framing skin as a biological gateway to broader healthspan applications. Its investment thesis spans six ecosystem verticals — devices, diagnostics, enhancement, regeneration, treatment, and prevention — with check sizes typically between $5 million and $15 million per company at pre-approval or Phase I/II development stages.
The firm does not develop proprietary technology; rather, it sources and supports science-led portfolio companies through a combination of direct capital, strategic guidance, and clinical validation via a seven-member Scientific Advisory Board chaired by Dr. Darrell Rigel and including dermatologists from Harvard, NYU, UCLA, and the University of Miami. Notable portfolio companies include Palvella Therapeutics (QTORIN rapamycin for rare skin diseases), Eirion Therapeutics (aesthetic dermatology including AI-09 neuromodulator and ET-02 hair-loss therapy), Novaestiq Corp. (Saypha injectable HA gels with Croma-Pharma, sold to Waldencast in July 2025), Sagesse Bio (RNAi focal-fat-reduction JV with Sirnaomics), AOA Dx (ovarian cancer liquid biopsy), and Avive Solutions (connected AED devices). Historical exits include BioXcel Therapeutics (~$60M IPO) and Castle Biosciences (~$64M IPO).
Gore Range generates revenue through standard VC economics: management fees on committed capital across Fund I (closed early 2019) and Fund II (nine-figure, nearly committed), plus carried interest on portfolio exits. The firm employs approximately 5 core investment professionals plus a CFO and senior advisors, and is reportedly evaluating a third fund to extend its skin-health-focused strategy. Customer concentration is moderate, with check sizes diversified across roughly 20 investments and six historical exits spanning biopharma, aesthetics, diagnostics, devices, and digital health.
Gore Range Capital firmographics
Firmographics- Name
- Gore Range Capital
- Legal name
- Gore Range Capital LLC
- Website
- https://gorerangecapital.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Gore Range Capital is a New York- and Southlake, Texas-based healthcare venture capital firm founded in 2015 that invests $5M–$15M in early-stage skin-health, regenerative medicine, and longevity companies, serving portfolio founders and limited partners through its Fund I and nine-figure Fund II.
- Ownership category
- akta.pro rank
Gore Range Capital industry classification
Industry- Product category
- Venture Capital / Healthcare Investment
- NAICS
- Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Corporate Strategic Real Assets & Infrastructure Venture Investing (FSANAHAN)
- akta.pro secondary industry
- Strategic / Balance-Sheet CVC (On-balance-sheet investing) (FSANAHAA)
Keywords
Where Gore Range Capital is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Gore Range Capital business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Revenue model
- Management Fees and Carried Interest: As a venture capital firm formed in 2015, Gore Range Capital generates revenue through management fees on committed capital and carried interest (performance fees) from successful portfolio company exits. Fund II is a nine-figure fund with second fund nearly committed.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels6 records
Gore Range Capital product offering
Product offeringCore offering
Gore Range Capital is a specialized healthcare venture capital firm that makes early-stage equity investments (typically $5M–$15M) into companies developing science-led platforms in precision health, regenerative medicine, personalized therapeutics, longevity, and skin health. The firm combines private equity operational discipline with a venture-style scientific partnership model, providing portfolio companies with strategic, financial, and clinical guidance across pre-approval and Phase I/II trial stages.
Product overview
Gore Range Capital is a specialized healthcare venture capital firm focused on skin health investments. The firm does not offer products or services directly; rather, it invests in portfolio companies developing healthcare solutions in precision health, regenerative medicine, personalized therapeutics, longevity, and restorative medical sciences. The portfolio includes companies such as Palvella Therapeutics (developing QTORIN rapamycin for rare skin diseases), Eirion Therapeutics (developing aesthetic dermatology products like ET-02 for hair loss), Sagesse Bio (developing SGY-101 for focal fat reduction), Novaestiq (developing Saypha injectable hyaluronic acid gels), and Avive Solutions (developing connected AED devices).
Differentiator
Problem solved
Functional benefit
Products and services
- Gore Range Capital Fund I Venture capital fund providing early-stage equity investments and operational support to healthcare companies focused on skin health and adjacent therapeutic areas. Target investors are limited partners seeking exposure to specialized healthcare innovation.
- Gore Range Capital Fund II Second venture capital fund of nine-figure size, making direct equity investments of $5M–$15M into early-stage healthcare companies developing next-generation skin health, precision health, regenerative medicine, and longevity platforms. Aimed at limited partners seeking returns from a focused dermatology and longevity thesis.
Quantifiable outcome
- 20 investments made across funds with 6 successful exits
- +2 more outcomes
Companies that use Gore Range Capital
Customer profileNamed customers8 records
Segments2 records
Ideal customer profiles2 records
Gore Range Capital technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Gore Range Capital partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor and core.
- Dermatology Summit / Advancing Innovation in DermatologyminorHumberto Antunes serves as member of Dermatology Summit Conference Board of Directors & Advisors and will moderate two sessions at 2026 summit in San Francisco including panels on dermatology business in Asia and challengers in aesthetic medicine.
- Waldencast plccoreAcquired Novaestiq Corp. (GRC Fund II portfolio company) in exchange for upfront cash, royalties in perpetuity based on net sales, and contingent issuance of up to 9.8M Waldencast class A shares on FDA approval and sales milestones. Novaestiq's Saypha injectables will be launched under Obagi Medical brand.
- Croma-Pharma GmbHcoreJoint venture partner in Novaestiq Corp., developing injectable hyaluronic acid gels (Saypha ChIQ and Saypha MagIQ) for US market. Croma brings 40 years of HA-based treatment expertise with over 110 million syringes produced and marketing in 80+ countries. Novaestiq was sold to Waldencast in July 2025 for combination of upfront cash, royalties, and contingent shares.
- SirnaomicscoreStrategic partnership to create Sagesse Bio, combining GRC's skin health expertise with Sirnaomics' cutting-edge RNAi technology to accelerate clinical development of novel solutions for focal fat reduction. Sirnaomics provides RNAi technology platform and scientific expertise; GRC contributes industry knowledge and operational support. Lead compound SGY-101 is IND-enabled and in Phase II clinical trials for other indications.
Scale indicators4 records
Recent moves7 records
Expansion highlights6 records
Gore Range Capital competitors and assessment
Company assessmentDirect peers
- venBio: Early-stage life sciences venture firm that backs clinical-stage biopharmaceutical companies, often with a focus on specific therapeutic verticals. Directly comparable to Gore Range in fund size, stage focus (Phase I/II assets), and the operating-partner model that supports portfolio companies through clinical development.
- Atlas Venture: Early-stage life sciences VC that builds and funds biotech companies from inception through clinical proof-of-concept. Comparable to Gore Range in targeting pre-approval and early clinical assets, providing operating support, and creating companies around specific scientific platforms.
- Medicxi: Healthcare-dedicated venture firm with deep dermatology and therapeutics expertise stemming from the Index Ventures life sciences franchise. Closely comparable to Gore Range's specialized dermatology/skin health investment focus and early-stage clinical asset strategy.
- 5AM Ventures: Early-stage life sciences VC investing in platform technologies and therapeutic assets at the preclinical-to-clinical inflection point. Directly comparable to Gore Range's $5-15M check size at key growth inflection points and hands-on operating partnership model.
- ARCH Venture Partners: Early-stage science and healthcare VC that creates and funds companies from breakthrough university and corporate research. Comparable to Gore Range's model of co-creating companies with strategic partners (e.g., Sirnaomics, Croma-Pharma) and supporting assets from inception through clinical milestones.
- Frazier Healthcare Partners: Healthcare-dedicated investment firm with both venture and growth funds covering therapeutics, medical devices, and diagnostics. Comparable to Gore Range's specialist healthcare mandate, with similar investment stages and operating-partner support for portfolio companies.
- Domain Associates: Healthcare-focused venture firm investing across therapeutic platforms, medical devices, and diagnostics from clinical development through commercialization. Directly comparable to Gore Range's clinical-stage focus and specialty healthcare model.
- Abingworth: Life sciences-focused investment firm with clinical translation and venture funds targeting therapeutics and digital health. Comparable to Gore Range's stage focus (early clinical through development), specialist healthcare mandate, and operating-partner engagement model.
Broad incumbents
- OrbiMed: One of the largest healthcare-dedicated investment firms globally, with multi-stage funds spanning venture, growth, and public equities across therapeutics, devices, and diagnostics. A broad incumbent operating in the same dermatology and aesthetics space but at materially larger fund sizes and broader mandate than Gore Range.
- New Enterprise Associates (NEA): One of the largest and most active venture capital firms with a longstanding healthcare and life sciences practice spanning biotech, medtech, and healthtech. A broad incumbent that competes for healthcare assets but at much larger fund sizes and across a far broader sector mandate than Gore Range's dermatology-focused thesis.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Gore Range Capital social profiles
Digital presenceGore Range Capital financial estimates
Financial estimateRevenue estimate
Valuation estimate
Gore Range Capital leadership team
Management profileNumber of profiles
Profiles7 records
Gore Range Capital funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Gore Range Capital M&A and investment
M&A and investmentM&A
Investments16 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Gore Range Capital
What does Gore Range Capital do?
Gore Range Capital is a specialized healthcare venture capital firm that makes early-stage equity investments (typically $5M–$15M) into companies developing science-led platforms in precision health, regenerative medicine, personalized therapeutics, longevity, and skin health. The firm combines private equity operational discipline with a venture-style scientific partnership model, providing portfolio companies with strategic, financial, and clinical guidance across pre-approval and Phase I/II trial stages.
Is Gore Range Capital a public or private company?
Gore Range Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Gore Range Capital founded?
Gore Range Capital was founded in 2015. It employs 1 to 10 people.
Where is Gore Range Capital based?
Gore Range Capital is headquartered in New York, United States, in the North America region.
How does Gore Range Capital make money?
One revenue line is on record: management Fees and Carried Interest.
Who are Gore Range Capital's main competitors?
Direct peers on record are venBio, Atlas Venture, Medicxi, 5AM Ventures, ARCH Venture Partners, Frazier Healthcare Partners, Domain Associates and Abingworth. Broad incumbents are OrbiMed and New Enterprise Associates (NEA).
Does Gore Range Capital have an API?
No public API is recorded for Gore Range Capital.
What industry is Gore Range Capital in?
Gore Range Capital's product category is Venture Capital / Healthcare Investment. Its primary akta.pro industry code is FSANAHAN, Corporate Strategic Real Assets & Infrastructure Venture Investing, with a secondary code of FSANAHAA, Strategic / Balance-Sheet CVC (On-balance-sheet investing). Its NAICS code is 523940 and its SIC code is 6282.